© 2022 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
July 01, 2022
Drs Mikhail Kosiborod and Neil Skolnik discuss this unique moment in the history of T2D management that offers treatments to address its broad cardiometabolic impact.
Influenza, PPSV23 Vaccines May Reduce Risk for COPD Exacerbations, Hospitalizations
July 01, 2022
In persons with COPD, seasonal influenza and PPSV23 vaccines, separately or together, reduced the risk for COPD- and pneumonia-related hospitalizations.
Study Pinpoints 6 Job-related Stressors Linked with Physician Suicide
June 30, 2022
Suicidal ideation affects 1 in 15 physicians and job-related stress is often a reason for a suicide among them. A new study set out to find specifics.
Glycopyrrolate/formoterol found Noninferior to Tiotropium/formoterol for Improving COPD Symptoms
June 30, 2022
Authors of this first study to compare the combinations head-to-head suggest that the glycopyrrolate combination is appropriate for long-term COPD management.
Stroke Patients Very Likely to Present with Undiagnosed Risk Factors
June 30, 2022
Three-quarters of stroke patients in a Swiss registry had at least 1 undiagnosed risk factor at the time of the event, most commonly hyperlipidemia or hypertension.
US Cardiovascular Health Remains Poor, Declines Begin in Early Childhood: American Heart Association Investigators
June 29, 2022
US CV health is well below ideal, with 80% of adults scoring as only low or moderate in the first published study using AHA's new Life's Essential 8 algorithm.
American Heart Association Announces "Life's Essential 8" Enhanced Cardiovascular Health Model
June 29, 2022
Slide Show: The AHA added sleep duration to its Life's Simple 7 cardiovascular health construct and updated sections on diet, lipids, blood glucose and smoking.
Gepant sNDA for Chronic Migraine: Atogepant from AbbVie
June 28, 2022
If the atogepant label is expanded, the drug will be the only gepant approved for the broad indication of prevention of both episodic and chronic migraine.
AbbVie's Risankizumab (Skyrizi) Approved to Treat Moderately to Severely Active Crohn Disease
June 28, 2022
The new approval for risankizumab makes it the only interleukin-23 inhibitor for moderately to severely active Crohn disease, according to AbbVie.
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
June 28, 2022
Lead author of a study of nearly 200 000 adults with type 2 diabetes that revealed significant clinical inertia in the critical period following initial diagnosis expands on the implications.